▁Process 10.375
▁Research 6.19140625
▁and 4.984375
▁Development 3.94921875
▁( 6.390625
PR 3.97265625
& 4.00390625
D 1.04296875
) 0.485595703125
▁plays 11.21875
▁a 1.5927734375
▁cru 3.73046875
cial 0.06805419921875
▁role 0.57958984375
▁in 0.4912109375
▁the 1.2451171875
▁ph 8.2421875
arma 0.98828125
ce 0.349609375
ut 0.1932373046875
ical 0.1138916015625
▁industry 2.412109375
. 1.20703125
▁It 2.90625
▁is 1.1728515625
▁responsible 2.994140625
▁for 0.06951904296875
▁developing 3.5625
▁efficient 6.96875
▁and 1.4638671875
▁cost 1.8681640625
- 0.27880859375
effect 0.050537109375
ive 0.00281524658203125
▁manufact 3.17578125
uring 0.007617950439453125
▁processes 1.1962890625
▁to 2.875
▁produce 2.3359375
▁active 4.8046875
▁ph 0.26904296875
arma 0.00125885009765625
ce 0.0033512115478515625
ut 0.0009336471557617188
ical 0.00676727294921875
▁ing 0.0635986328125
red 0.0021991729736328125
ients 0.037078857421875
▁( 0.77685546875
API 0.01512908935546875
s 0.241943359375
) 0.472900390625
▁and 0.990234375
▁drug 4.3046875
▁products 1.3896484375
. 0.80615234375
▁PR 2.201171875
& 0.083984375
D 0.00849151611328125
▁influ 9.6484375
ences 0.00022470951080322266
▁the 0.7783203125
▁drug 3.4609375
▁development 1.1162109375
▁tim 4.703125
eline 0.93798828125
▁by 2.02734375
▁optim 3.90234375
izing 0.040924072265625
▁the 0.9462890625
▁manufact 1.9296875
uring 0.01441192626953125
▁process 1.2451171875
▁in 3.84375
▁parallel 3.779296875
▁with 0.47705078125
▁the 1.0556640625
▁clin 1.5673828125
ical 0.0078887939453125
▁development 1.4873046875
▁of 2.078125
▁a 1.154296875
▁new 1.1630859375
▁chemical 5.58203125
▁entity 0.0110321044921875
▁( 0.50048828125
N 0.131103515625
CE 0.0191802978515625
). 0.373046875
▁This 3.5078125
▁parallel 7.44921875
▁processing 6.41015625
▁acceler 5.37890625
ates 0.00553131103515625
▁the 0.319091796875
▁overall 3.01953125
▁tim 1.578125
eline 0.167236328125
▁from 3.30078125
▁drug 2.4140625
▁discovery 0.75927734375
▁to 0.276611328125
▁market 1.6923828125
. 3.279296875
▁▁▁ 11.78125
<0x0A> 0.35107421875
<0x0A> 0.339599609375
The 2.1171875
▁main 4.83984375
▁sections 7.62109375
▁within 6.69921875
▁PR 1.1357421875
& 0.01226043701171875
D 0.001617431640625
▁include 1.896484375
▁process 3.1171875
▁research 2.81640625
, 1.0703125
▁process 0.64501953125
▁development 0.62353515625
, 0.1373291015625
▁and 1.6669921875
▁pilot 5.91796875
▁plant 0.76611328125
▁operations 1.6123046875
. 0.183837890625
▁Process 1.919921875
▁research 0.146240234375
▁focus 2.25
es 0.0018167495727539062
▁on 0.018402099609375
▁developing 2.4140625
▁innov 4.51953125
ative 0.0455322265625
▁manufact 1.81640625
uring 0.0003643035888671875
▁processes 1.0810546875
▁for 2.068359375
▁APIs 2.0390625
▁and 0.72314453125
▁drug 0.505859375
▁products 0.0736083984375
. 0.54931640625
▁They 5.4921875
▁aim 3.6640625
▁to 0.15771484375
▁design 4.41015625
▁synth 7.234375
etic 0.65625
▁routes 1.0126953125
, 1.2744140625
▁identify 4.04296875
▁critical 4.2890625
▁process 1.60546875
▁parameters 0.28369140625
, 0.234375
▁and 0.439453125
▁optimize 1.349609375
▁reaction 4.66015625
▁conditions 0.55029296875
. 0.8212890625
▁Process 1.1728515625
▁development 0.2213134765625
▁further 6.2734375
▁scales 7.7734375
▁up 0.6689453125
▁and 2.4453125
▁optim 1.0048828125
izes 0.0027065277099609375
▁the 0.6279296875
▁processes 4.03125
▁developed 2.724609375
▁by 3.298828125
▁process 0.763671875
▁research 0.003124237060546875
. 0.70849609375
▁They 1.78515625
▁determine 5.43359375
▁the 0.65771484375
▁critical 3.263671875
▁process 1.65625
▁parameters 0.11346435546875
▁and 1.166015625
▁specific 7.11328125
ations 0.55078125
▁to 2.734375
▁control 4.39453125
▁vari 6.77734375
ability 0.08099365234375
. 1.9462890625
▁Pil 2.64453125
ot 0.00019097328186035156
▁plant 0.222900390625
▁operations 0.032501220703125
▁verify 6.765625
▁the 0.5537109375
▁robust 4.2421875
ness 0.018890380859375
▁of 0.30029296875
▁the 0.468017578125
▁optimized 4.41015625
▁process 0.73046875
▁at 4.0625
▁a 1.4951171875
▁larger 2.677734375
▁scale 0.051513671875
. 0.54150390625
▁They 1.9970703125
▁produce 5.671875
▁batch 2.6328125
es 0.36669921875
▁of 0.259765625
▁APIs 2.416015625
▁and 0.453125
▁drug 0.343505859375
▁products 0.04986572265625
▁for 1.7490234375
▁clin 2.982421875
ical 0.0006837844848632812
▁tri 0.7236328125
als 4.9948692321777344e-05
▁and 0.91357421875
▁stability 4.76953125
▁testing 1.36328125
. 0.2451171875
<0x0A> 2.662109375
<0x0A> 0.05255126953125
PR 2.880859375
& 0.01021575927734375
D 0.0009860992431640625
▁can 3.86328125
▁decrease 9.359375
▁development 3.765625
▁time 0.9873046875
▁and 1.263671875
▁increase 2.173828125
▁pipeline 7.296875
▁output 3.51953125
▁in 4.43359375
▁several 3.6796875
▁ways 0.256591796875
. 0.22021484375
▁First 1.201171875
ly 1.91015625
, 0.007785797119140625
▁beginning 11.5234375
▁process 3.669921875
▁research 0.2469482421875
▁and 1.8056640625
▁development 1.046875
▁early 2.505859375
▁in 0.367919921875
▁the 0.297119140625
▁drug 0.226806640625
▁discovery 0.8154296875
▁phase 2.677734375
▁allows 2.298828125
▁for 1.537109375
▁parallel 3.9921875
▁processing 1.91796875
▁which 5.671875
▁saves 4.625
▁time 0.287841796875
. 1.6201171875
▁Second 0.7685546875
ly 0.0587158203125
, 0.0019378662109375
▁using 4.33984375
▁tools 7.16015625
▁like 1.7001953125
▁computational 3.6171875
▁model 1.8076171875
ing 0.00380706787109375
▁and 1.1171875
▁continuous 6.51953125
▁processing 2.548828125
▁can 2.21875
▁acceler 2.06640625
ate 0.0012159347534179688
▁process 2.5703125
▁research 1.353515625
. 1.45703125
▁Third 1.5009765625
ly 0.027313232421875
, 0.0018987655639648438
▁quality 7.4296875
▁by 3.44140625
▁design 0.0038928985595703125
▁( 0.95458984375
Q 0.004131317138671875
b 0.08514404296875
D 0.00016796588897705078
) 0.052642822265625
▁and 2.546875
▁design 4.0703125
▁of 0.6201171875
▁experiments 0.156005859375
▁( 0.261962890625
Do 0.242431640625
E 0.02691650390625
) 0.023284912109375
▁help 3.322265625
▁optimize 2.615234375
▁processes 2.912109375
▁faster 7.52734375
▁while 4.8828125
▁building 7.25
▁quality 5.1171875
▁into 0.8935546875
▁the 0.348388671875
▁process 0.794921875
. 0.4599609375
▁Four 2.1875
th 0.00021076202392578125
ly 0.0270538330078125
, 0.003215789794921875
▁util 4.453125
izing 0.043731689453125
▁platform 7.125
▁techn 0.1959228515625
ologies 0.00040030479431152344
▁can 2.650390625
▁exped 5.4921875
ite 0.0007314682006835938
▁the 1.0986328125
▁development 1.2509765625
▁of 0.51025390625
▁similar 6.234375
▁mole 3.990234375
cules 0.05517578125
. 1.1044921875
▁Finally 1.7158203125
, 0.0022983551025390625
▁se 7.59765625
am 0.208984375
less 0.194091796875
▁technology 5.32421875
▁transfer 1.052734375
▁from 1.533203125
▁PR 7.41015625
& 0.00969696044921875
D 0.0011587142944335938
▁to 0.33056640625
▁manufact 1.4609375
uring 0.0106658935546875
▁ens 3.71875
ures 0.0007333755493164062
▁efficient 3.66796875
▁scale 2.181640625
- 0.315185546875
up 0.0274200439453125
▁and 1.2744140625
▁reduced 5.29296875
▁tim 4.796875
elines 0.233642578125
. 0.358154296875
<0x0A> 0.849609375
<0x0A> 0.041473388671875
An 5.30859375
▁example 1.6455078125
▁of 0.10565185546875
▁how 3.05078125
▁PR 0.186767578125
& 0.0017499923706054688
D 0.0003490447998046875
▁solved 9.0859375
▁a 0.61865234375
▁manufact 2.837890625
uring 0.0018815994262695312
▁problem 0.91259765625
▁is 0.77099609375
▁with 3.513671875
▁the 1.0224609375
▁development 1.6142578125
▁of 0.057220458984375
▁a 1.8701171875
▁modified 6.16015625
- 3.07421875
release 0.1710205078125
▁dos 3.21875
age 0.18115234375
▁form 0.040008544921875
▁of 1.5322265625
▁an 2.3515625
▁API 2.458984375
▁that 3.9140625
▁showed 6.4921875
▁poor 5.95703125
▁flow 5.94921875
▁properties 1.908203125
▁and 2.40234375
▁content 8.859375
▁uniform 1.0302734375
ity 0.0058746337890625
▁issues 4.92578125
. 0.5625
▁The 1.2265625
▁PR 2.521484375
& 0.0040283203125
D 0.00030231475830078125
▁team 0.287109375
▁used 2.728515625
▁Q 4.26171875
b 0.0140228271484375
D 0.00017523765563964844
▁to 1.1318359375
▁study 5.58203125
▁the 0.3779296875
▁impact 3.84765625
▁of 0.1121826171875
▁raw 4.88671875
▁materials 1.4189453125
▁and 1.265625
▁processing 3.03125
▁parameters 1.9521484375
▁on 0.1998291015625
▁the 0.87646484375
▁critical 7.5234375
▁quality 4.41796875
▁attributes 0.051666259765625
▁( 0.53759765625
C 0.01232147216796875
Q 0.0031337738037109375
As 0.42041015625
) 0.445556640625
▁of 0.32861328125
▁the 0.238525390625
▁API 1.8447265625
. 0.35595703125
▁They 0.84228515625
▁identified 1.99609375
▁the 1.234375
▁source 4.5
▁of 0.170654296875
▁vari 4.36328125
ability 0.00643157958984375
▁and 0.79443359375
▁adjust 3.8984375
ed 0.006855010986328125
▁the 0.4404296875
▁process 0.90185546875
▁parameters 0.841796875
▁accordingly 1.162109375
▁to 1.244140625
▁achieve 2.171875
▁the 1.2998046875
▁target 2.712890625
▁product 3.181640625
▁profile 1.322265625
. 0.859375
▁Add 8.015625
itional 0.048553466796875
▁experiments 5.21484375
▁at 5.10546875
▁pilot 1.78125
▁scale 1.0830078125
▁valid 2.87109375
ated 0.0007066726684570312
▁the 0.206787109375
▁robust 3.060546875
ness 0.032073974609375
▁of 0.0655517578125
▁the 0.046234130859375
▁optimized 1.7978515625
▁process 0.1287841796875
. 0.450439453125
▁The 1.318359375
▁implementation 7.73828125
▁of 0.057769775390625
▁the 1.376953125
▁new 2.732421875
▁process 0.40234375
▁and 3.2734375
▁specific 7.7734375
ations 0.01068115234375
▁enabled 3.640625
▁the 0.66162109375
▁successful 4.37109375
▁development 2.029296875
▁of 0.197265625
▁the 1.029296875
▁modified 0.5712890625
- 0.237060546875
release 0.002147674560546875
▁product 4.5234375
. 0.6728515625
<0x0A> 0.92919921875
<0x0A> 0.0227813720703125
In 3.349609375
▁summary 1.7177734375
, 0.003917694091796875
▁PR 0.387451171875
& 0.0014486312866210938
D 0.00032782554626464844
▁plays 2.177734375
▁an 1.658203125
▁integral 2.078125
▁role 0.04949951171875
▁in 0.037017822265625
▁bringing 4.76171875
▁a 1.6904296875
▁new 0.70849609375
▁drug 0.98095703125
▁to 0.68310546875
▁market 0.487548828125
▁by 2.525390625
▁developing 1.876953125
▁and 2.5234375
▁optim 1.1298828125
izing 0.0004363059997558594
▁manufact 1.181640625
uring 0.0005736351013183594
▁processes 0.096923828125
▁in 2.697265625
▁parallel 0.0228271484375
▁with 0.135498046875
▁clin 1.1943359375
ical 0.00034999847412109375
▁development 0.462890625
. 0.2196044921875
▁ 2.890625
▁Using 5.6015625
▁modern 3.806640625
▁tools 2.01171875
▁and 1.09765625
▁platforms 2.166015625
, 0.76806640625
▁PR 0.4189453125
& 0.0003643035888671875
D 0.00025653839111328125
▁can 1.568359375
▁significantly 3.734375
▁acceler 1.466796875
ate 0.0004105567932128906
▁ph 6.94140625
arma 0.0016765594482421875
ce 0.039398193359375
ut 1.4424324035644531e-05
ical 0.0005259513854980469
▁development 0.55322265625
▁tim 3.33984375
elines 0.0217437744140625
▁and 1.208984375
▁boost 6.1875
▁pipeline 1.638671875
▁product 4.1328125
ivity 0.021209716796875
. 0.10546875
▁With 5.52734375
▁the 1.1728515625
▁increasing 3.21484375
▁complexity 1.4755859375
▁of 0.1517333984375
▁drug 1.4658203125
▁mole 3.20703125
cules 0.00835418701171875
▁and 0.833984375
▁delivery 6.08203125
▁techn 4.15234375
ologies 0.0005645751953125
, 0.05206298828125
▁the 2.052734375
▁role 2.427734375
▁of 0.06646728515625
▁PR 0.061767578125
& 0.0007033348083496094
D 0.00023663043975830078
▁will 1.6787109375
▁become 2.05078125
▁even 0.8466796875
▁more 0.0113983154296875
▁cru 1.9345703125
cial 6.306171417236328e-05
▁to 2.0625
▁translate 7.2265625
▁innov 2.564453125
ative 0.61376953125
▁ther 3.89453125
ap 0.0142822265625
ies 4.4345855712890625e-05
▁to 1.185546875
▁patients 0.6005859375
. 0.48193359375
